New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

Eisenhauer, Elizabeth; Therasse, Patrick; Bogaerts, Jan; Schwartz, Lawrence H.; Sargent, Daniel J.; Ford, Robert; Dancey, Janet; Arbuck, Susan G.; Gwyther, Stephen J.; Mooney, Margaret; Rubinstein, Larry; Shankar, Lalitha; Dodd, Lori E.; Kaplan, Richard; Lacombe, Denis; Verweij, Jaap

doi:10.1016/j.ejca.2008.10.026

Cited by 23,678 publications

(18,219 citation statements)

References 25 publications

Supporting

Mentioning

17,932

Contrasting

Unclassified

196

Order By: Relevance

“…The treatment details are summarized in Table 2. Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines25 were used to categorize patients into groups (i.e., progressive disease [PD], stable disease [SD], partial response [PR], or complete response [CR]) based on the 18 F‐fluorodeoxyglucose ( 18 F‐FDG) positron emission tomography/computed tomography (PET)/CT, performed 3–6 months after treatment completion.…”

Section: Methodsmentioning

confidence: 99%

Intravoxel incoherent motion diffusion‐weighted MRI during chemoradiation therapy to characterize and monitor treatment response in human papillomavirus head and neck squamous cell carcinoma

Paudyal

Riaz

et al. 2016

Magnetic Resonance Imaging

View full text Add to dashboard Cite

PurposeCharacterize and monitor treatment response in human papillomavirus (HPV) head and neck squamous cell carcinoma (HNSCC) using intra‐treatment (intra‐TX) imaging metrics derived from intravoxel incoherent motion (IVIM) diffusion‐weighted magnetic resonance imaging (DW‐MRI).Materials and MethodsThirty‐four (30 HPV positive [+] and 4 HPV negative [‐]) HNSCC patients underwent a total of 136 MRI including multi‐b value DW‐MRI (pretreatment [pre‐TX] and intra‐TX weeks 1, 2, and 3) at 3.0 Tesla. All patients were treated with chemo‐radiation therapy. Monoexponential (yielding apparent diffusion coefficient [ADC]) and bi‐exponential (yielding perfusion fraction [f], diffusion [D], and pseudo‐diffusion [D*] coefficients) fits were performed on a region of interest and voxel‐by‐voxel basis, on metastatic neck nodes. Response was assessed using RECISTv1.1. The relative percentage change in D, f, and D* between the pre‐ and intra‐TX weeks were used for hierarchical clustering. A Wilcoxon rank‐sum test was performed to assess the difference in metrics within and between the complete response (CR) and non‐CR groups.ResultsThe delta (Δ) change in volume (V)1wk‐0wk for the CR group differed significantly (P = 0.016) from the non‐CR group, while not for V2wk‐0wk and V3wk‐0wk (P > 0.05). The mean increase in ΔD3wk‐0wk for the CR group was significantly higher (P = 0.017) than the non‐CR group. ADC and D showed an increasing trend at each intra‐TX week when compared with pre‐TX in CR group (P < 0.003). Hierarchical clustering demonstrated the existence of clusters in HPV + patients.ConclusionAfter appropriate validation in a larger population, these IVIM imaging metrics may be useful for individualized treatment in HNSCC patients. Level of Evidence: 2J. Magn. Reson. Imaging 2017;45:1013–1023

show abstract

Section: Methodsmentioning

confidence: 99%

Intravoxel incoherent motion diffusion‐weighted MRI during chemoradiation therapy to characterize and monitor treatment response in human papillomavirus head and neck squamous cell carcinoma

Paudyal

Riaz

et al. 2016

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…Response was assessed according to response evaluation criteria in solid tumors (RECIST) guidelines 24, 25, 26, 27. In dogs with lymph node metastasis, lymph nodes were included in the response assessment.…”

Section: Methodsmentioning

confidence: 99%

Randomized Phase III Trial of Piroxicam in Combination with Mitoxantrone or Carboplatin for First‐Line Treatment of Urogenital Tract Transitional Cell Carcinoma in Dogs

Allstadt

Rodríguez

Boostrom

et al. 2015

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundReported response rates of transitional cell carcinoma (TCC) in dogs to piroxicam in combination with either mitoxantrone or carboplatin are similar; however, it is unknown whether either drug might provide superior duration of response.Hypothesis/ObjectivesTo determine if the progression‐free interval (PFI) of dogs with TCC treated with mitoxantrone and piroxicam was different than that of dogs receiving carboplatin and piroxicam. The hypothesis was that the efficacy of mitoxantrone is no different from carboplatin.AnimalsFifty dogs with TCC without azotemia.MethodsProspective open‐label phase III randomized study. Either mitoxantrone or carboplatin was administered every 3 weeks concurrently with piroxicam with restaging at 6‐week intervals. Twenty‐four dogs received carboplatin and 26 received mitoxantrone.ResultsResponse was not different between groups (P = .56). None of the dogs showed complete response. In the mitoxantrone group, there were 2 (8%) partial responses (PR) and 18 (69%) dogs with stable disease (SD). In the carboplatin group, there were 3 PR (13%) and 13 (54%) dogs with SD. The PFI was not significantly different between groups (mitoxantrone = 106 days; carboplatin = 73.5 days; P = .62; hazard ratio 0.86; 95% confidence interval 0.47–1.56). Dogs with prostatic involvement experienced a shorter survival (median, 109 days) compared to dogs with urethral, trigonal, or apically located tumors; this difference was significant (median 300, 190, and 645 days, respectively; P = .005).Conclusions and Clinical ImportanceThis study did not detect a different in outcome in dogs with TCC treated with either mitoxantrone or carboplatin in combination with piroxicam.

show abstract

“…Patients were administered a dose of 800 mg of pazopanib once daily that was reduced in case of intolerance. Treatment was stopped because of unacceptable toxicity, withdrawal of consent for any reason, or disease progression (PD) assessed through RECIST 1.1 17. No dose interruptions were reported within the dataset despite the events listed above.…”

Section: Methodsmentioning

confidence: 99%

Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma

Ouerdani

Struemper

Suttle

et al. 2015

CPT Pharmacometrics Syst. Pharmacol.

View full text Add to dashboard Cite

The objective was to leverage tumor size data from preclinical experiments to propose a model of tumor growth and angiogenesis inhibition for the analysis of pazopanib efficacy in renal cell carcinoma (RCC) patients. We analyzed tumor data in mice with RCC CAKI‐2 cell line treated with pazopanib. Clinical tumor size data obtained in a subset of patients with RCC were also analyzed. A model accounting for the processes of tumor growth, angiogenesis, and drug effect was developed. The final tumor model was composed of two variables: the tumor and its vasculature. Our results show that, both in mice and in humans, pazopanib exhibits a dual mechanism of action, and parameter estimation values highlight the inherent difference between mice and humans on the time scale of tumor size response. We developed a semimechanistic tumor growth inhibition model that takes into account tumor angiogenesis in order to describe the effects of pazopanib in mice. Analyzing rich preclinical data with a semimechanistic model may be a relevant approach to facilitate the description of sparse clinical longitudinal tumor size data and to provide insights for the understanding of the drug mechanisms of action in patients.

show abstract

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

Cited by 23,678 publications

References 25 publications

Intravoxel incoherent motion diffusion‐weighted MRI during chemoradiation therapy to characterize and monitor treatment response in human papillomavirus head and neck squamous cell carcinoma

Intravoxel incoherent motion diffusion‐weighted MRI during chemoradiation therapy to characterize and monitor treatment response in human papillomavirus head and neck squamous cell carcinoma

Randomized Phase III Trial of Piroxicam in Combination with Mitoxantrone or Carboplatin for First‐Line Treatment of Urogenital Tract Transitional Cell Carcinoma in Dogs

Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma

Contact Info

Product

Resources

About